Skip to content
DraconiticResearch
Search Sources API
197,768 studies31 sourcesUpdated 24 min ago
Peer-reviewedCC BY 4.0Frontiers in Pharmacology

BL-DVDMS-mediated photodynamic therapy induces oxidative response associated with cellular senescence via p53/GADD45A signaling in lung cancer

  1. 1Department of Thoracic Surgery, Tangdu Hospital, The Fourth Military Medical University
  2. 2Department of Urology, First Affiliated Hospital, Xi’an Jiaotong University

Abstract

Current chemotherapy options for lung cancer (LC) are limited by poor tumor selectivity, systemic toxicity, and acquired resistance. Photodynamic therapy (PDT) offers a promising minimally invasive modality as a potential conservative or complementary approach, yet its clinical adoption has been constrained by suboptimal photosensitizers and unclear mechanisms. This study investigated a novel PDT regimen combining a 450 nm blue laser with the photosensitizer sinoporphyrin sodium (DVDMS) to address these limitations in LC. Our findings demonstrate that BL-DVDMS treatment selectively inhibits lung cancer cell proliferation while sparing normal bronchial epithelial cells. Low-dose PDT induces a moderate oxidative stress response, leading to DNA damage and G2/M cell cycle arrest. Importantly, this treatment triggers a senescence-associated phenotype, evidenced by increased SA-β-Gal activity and elevated secretion of SASP factors (IL-6, IL-8), accompanied by altered p53/GADD45 A signaling. These effects are abrogated by ROS scavenging or p53 inhibition, indicating that the oxidative response plays a central role in the observed antitumor activity. In the subcutaneous xenograft model, this regimen significantly suppresses tumor growth with no detectable systemic toxicity. Collectively, this work identifies BL-DVDMS-mediated PDT as a mechanistically defined, senescence-associated therapeutic strategy. This study provides a potential complementary treatment option for inoperable LC patients, particularly for managing residual disease and enhancing existing therapies.

Related

  1. Effects of Antimicrobial Photodynamic Therapy Mediated by Free Curcumin and Curcumin-Associated Superparamagnetic Iron Oxide Nanoparticles on Candida spp. and Microcosm Biofilms Associated with Denture Stomatitis
    Amanda Siqueira Fraga, Anna Carolina Pinheiro Lage, Karoline Kristina Kemmerich +5
    ACS omegaPeer-reviewedCC BYFull textGeneral medicineEurope PMCCrossref
  2. ZnPc(Lys)₅-mediated photodynamic inactivation and reduction of Candida albicans biofilm-associated cells in vitro and in vivo.
    Danlin Li, Fang Yuan, Yuchen Yang +6
    Frontiers in bioengineering and biotechnologyPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  3. Chronic exposure to the tire-wear contaminant 6-PPDQ induces senescence-associated biomarkers and neurobehavioral deficits: Involvement of ABL1-p53-autophagy signaling
    Zejiang Ma, Manxue Bai, Chunmei Xia +2
    Ecotoxicology and Environmental SafetyPeer-reviewedCC BYFull textPharmacology & toxicologyDOAJ
  4. Integrated Single-Cell and Spatial Transcriptomics Reveal Convergence on a Senescence-Associated B Cell-MIF Signaling Axis in Joint Aging and Osteoarthritis Progression.
    Weida Li, Yi Wang, Yongqing You +9
    Advanced science (Weinheim, Baden-Wurttemberg, Germany)Peer-reviewedCC BYFull textGeneral medicineEurope PMCPMC
  5. Rasagiline suppresses glioblastoma cell survival through oxidative stress-mediated modulation of TLR4/NF-Κb signaling and apoptosis
    Guven Akcay, Omer Faruk Anakok, Mustafa Ozkaraca +4
    Scientific ReportsPeer-reviewedCC BY 4.0Full textHuman geneticsCrossref
BibTeX
@article{li2026bldvdmsmediated,
  title = {{BL-DVDMS-mediated photodynamic therapy induces oxidative response associated with cellular senescence via p53/GADD45A signaling in lung cancer}},
  author = {Xing Li and Minghai Ma and Yibo Mei and Pan Zhang and Xiao Liang and Rou Huang and Yuanquan Zhang and Dalin He and Lei Wang},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  month = oct,
  doi = {10.3389/fphar.2026.1935296},
  url = {https://www.frontiersin.org/articles/10.3389/fphar.2026.1935296/full},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - BL-DVDMS-mediated photodynamic therapy induces oxidative response associated with cellular senescence via p53/GADD45A signaling in lung cancer
AU  - Xing Li
AU  - Minghai Ma
AU  - Yibo Mei
AU  - Pan Zhang
AU  - Xiao Liang
AU  - Rou Huang
AU  - Yuanquan Zhang
AU  - Dalin He
AU  - Lei Wang
PY  - 2026
DA  - 2026/10/28
JO  - Frontiers in Pharmacology
DO  - 10.3389/fphar.2026.1935296
UR  - https://www.frontiersin.org/articles/10.3389/fphar.2026.1935296/full
AB  - Current chemotherapy options for lung cancer (LC) are limited by poor tumor selectivity, systemic toxicity, and acquired resistance. Photodynamic therapy (PDT) offers a promising minimally invasive modality as a potential conservative or complementary approach, yet its clinical adoption has been constrained by suboptimal photosensitizers and unclear mechanisms. This study investigated a novel PDT regimen combining a 450 nm blue laser with the photosensitizer sinoporphyrin sodium (DVDMS) to address these limitations in LC. Our findings demonstrate that BL-DVDMS treatment selectively inhibits lung cancer cell proliferation while sparing normal bronchial epithelial cells. Low-dose PDT induces a moderate oxidative stress response, leading to DNA damage and G2/M cell cycle arrest. Importantly, this treatment triggers a senescence-associated phenotype, evidenced by increased SA-β-Gal activity and elevated secretion of SASP factors (IL-6, IL-8), accompanied by altered p53/GADD45 A signaling. These effects are abrogated by ROS scavenging or p53 inhibition, indicating that the oxidative response plays a central role in the observed antitumor activity. In the subcutaneous xenograft model, this regimen significantly suppresses tumor growth with no detectable systemic toxicity. Collectively, this work identifies BL-DVDMS-mediated PDT as a mechanistically defined, senescence-associated therapeutic strategy. This study provides a potential complementary treatment option for inoperable LC patients, particularly for managing residual disease and enhancing existing therapies.
SN  - 1663-9812
ER  -